- Home
- CWD vs BGLC Comparison
CWD vs BGLC Comparison
Compare CWD & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWD
- BGLC
- Stock Information
- Founded
- CWD 2009
- BGLC 2017
- Country
- CWD United States
- BGLC Malaysia
- Employees
- CWD N/A
- BGLC N/A
- Industry
- CWD Real Estate
- BGLC Medical Specialities
- Sector
- CWD Finance
- BGLC Health Care
- Exchange
- CWD Nasdaq
- BGLC Nasdaq
- Market Cap
- CWD 6.2M
- BGLC 5.8M
- IPO Year
- CWD 2023
- BGLC N/A
- Fundamental
- Price
- CWD $3.85
- BGLC $2.85
- Analyst Decision
- CWD
- BGLC
- Analyst Count
- CWD 0
- BGLC 0
- Target Price
- CWD N/A
- BGLC N/A
- AVG Volume (30 Days)
- CWD 48.2K
- BGLC 86.5K
- Earning Date
- CWD 05-15-2025
- BGLC 05-27-2025
- Dividend Yield
- CWD N/A
- BGLC N/A
- EPS Growth
- CWD N/A
- BGLC N/A
- EPS
- CWD N/A
- BGLC N/A
- Revenue
- CWD $51,119,000.00
- BGLC $9,265,870.00
- Revenue This Year
- CWD N/A
- BGLC N/A
- Revenue Next Year
- CWD $35.72
- BGLC N/A
- P/E Ratio
- CWD N/A
- BGLC N/A
- Revenue Growth
- CWD N/A
- BGLC N/A
- 52 Week Low
- CWD $4.00
- BGLC $2.01
- 52 Week High
- CWD $20.80
- BGLC $8.40
- Technical
- Relative Strength Index (RSI)
- CWD 28.27
- BGLC 50.58
- Support Level
- CWD $3.75
- BGLC $2.85
- Resistance Level
- CWD $4.46
- BGLC $3.25
- Average True Range (ATR)
- CWD 0.67
- BGLC 0.26
- MACD
- CWD 0.14
- BGLC 0.03
- Stochastic Oscillator
- CWD 10.09
- BGLC 40.09
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.